Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008

Diabetic Medicine : a Journal of the British Diabetic Association
C J CurrieM Evans

Abstract

A variety of influences determine prescribing behaviour. The purpose of this study was to characterize the pattern of dispensing for glucose-lowering and monitoring in the UK from 2000 to 2008, inclusively. Open source data were used from the four UK prescription pricing agencies. Historical patterns of dispensing change were analysed in England, thus data are for England unless otherwise stated. Costs were adjusted for price inflation and reported in UK pound at 2008 prices. The total cost in the UK in 2008 was 702 239 000 UK pounds: 22 897 000 pounds (3.2%) for Northern Ireland, 37 681 000 pounds (5.3%) for Wales, 57 146 000 pounds (8.1%) for Scotland and 590 514 000 pounds (83.4%) for England. As a per cent of the overall primary care drug budget for each region, this represented 6.9% overall and then 5.8, 6.5, 5.9 and 7.1%, respectively. In England, diabetes-related dispensing costs increased from 290m to 591m UK pounds. All glucose-lowering drug classes increased in volume, except the alpha-glucoside inhibitors and the prandial glucose regulators. Insulin costs increased from 128m to 286m UK pounds. Insulin glargine metrics increased year-on-year, whereas neutral protamine Hagedorn (NPH) declined. Analogue insulin increase...Continue Reading

References

Nov 2, 2001·The Journal of the Royal Society for the Promotion of Health·A le May
Jan 18, 2002·Journal of Urban Health : Bulletin of the New York Academy of Medicine·UNKNOWN New York City Department of Health HIV Epidemiology Group
Apr 22, 2006·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Robert E Ratner, UNKNOWN Diabetes Prevention Program Research
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski
Jun 7, 2007·The New England Journal of Medicine·David M Nathan
Apr 12, 2008·Drug and Therapeutics Bulletin
Jul 3, 2008·Current Opinion in Endocrinology, Diabetes, and Obesity·Spiros FourlanosPeter G Colman
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Jun 16, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·C L MorganC J Currie
Jul 27, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·C J CurrieC D Poole

❮ Previous
Next ❯

Citations

Oct 19, 2011·International Journal of Technology Assessment in Health Care·Lisa IrvineMike Sampson
Jul 5, 2013·QJM : Monthly Journal of the Association of Physicians·T A Chowdhury, P Bennett-Richards
Feb 2, 2013·The Journal of Clinical Endocrinology and Metabolism·Craig J CurrieChristopher Ll Morgan
Feb 10, 2016·The Lancet. Diabetes & Endocrinology·David BeranRichard Laing
Aug 21, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·E A M Gale
Aug 21, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·A M Gray
Oct 12, 2018·Tropical Medicine & International Health : TM & IH·Zongjie LiYu Fang
Sep 8, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Peter EibichAlastair M Gray
Jul 27, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·C J CurrieC D Poole
Aug 21, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·C Ll MorganC J Currie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.